Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Fortune 500
Fortune 500
Fortune 500 U.S.
Fortune Global 500
Fortune 500 Europe
Fortune China 500
Fortune SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Paul Hudson
Stay informed with Paul Hudson’s coverage and analysis for Fortune.
Commentary
AI might beat IQ, not EQ — but never say never
By
Paul Hudson
Commentary
Sanofi CEO: AI promises a great era of drug discovery that could fundamentally change medicine–but only if we allow it to deliver
By
Paul Hudson
Commentary
Sanofi and Insight Enterprises CEOs: With the right blueprint in place, AI will empower workers and help big companies become more nimble
By
Paul Hudson
and
Joyce Mullen
Commentary
Climate change is our greatest health crisis. The same investments can often address both threats
By
Vanessa Kerry
and
Paul Hudson
Commentary
Sanofi CEO: ‘Europe’s lead in life sciences R&D is eroding–but co-localized hubs could allow it to keep up’
By
Paul Hudson
Commentary
People are much less likely to trust the medical system if they are from an ethnic minority, have disabilities, or identify as LGBTQ+, according to a first-of-its-kind study by Sanofi
By
Paul Hudson
and
Michelle A. Williams
Commentary
Pharma’s sense of urgency must outlast the pandemic
By
Paul Hudson
Commentary
How new technologies are transforming cancer treatment
By
Paul Hudson
Commentary
How to speed up medical breakthroughs in the post-COVID world
By
Paul Hudson
Commentary
Sanofi CEO: How we can prevent being caught off guard by a pandemic like the coronavirus ever again
By
Paul Hudson
Commentary
Pharma needs to stop chasing shiny objects and start embracing practical technology
By
Paul Hudson